3 adeno patients had detectable hexon-specific response (11 SFC/ 1Â10e5 cells), however, none of the 5 CMV+ patients had any detectable SFC. However, after 9-12 days of stimulation we could enumerate CTLp in 7/8 patients. For adenovirus, the median hexon-specific response was 52 SFC/1Â10e5 SFC (range 20-90), and the penton-specific CTLp frequency was 13 SFC/1Â10e5 (1 -25) . The median CMV pp65-specific response was 6.7 . No responses were recorded against CMV EI-1 demonstrating the critical role of antigenic restimulation by the Ad5f35pp65 construct lacking IE. Smilarly in the adeno+/CMVpatients we detected SFC solely against hexon and/or penton. All patients are surviving at a median of 220 days after transplant (range 81-532). Conclusion: To our knowledge these are the first data demonstrating that dormant virus-specific CTLp are present already in the first 2-3 months in most adenovirus or CMV infected UCBT recipients (7/8 in this dataset). Although these rare events are below detection by standard ELISPOT the feasibility of their ex vivo expansion may lead to adoptive therapies. In lung transplantation, early infection (\100 d) with a common respiratory virus (RV) is associated with acute or chronic rejection, presenting as Bronchiolitis Obliterans (BO). After hematopoietic stem cell transplantation (HSCT) alloimmune lung syndromes (allo-LS), including Idiopathic Pneumonia Syndrome (IPS; acute) and BO (chronic), also occur, but the role of RV is unclear. In this prospective cohort study we analyzed the influence of common RV early (\ 100 days) after HSCT, on the development of allo-LS and survival. 110 paediatric patients with a median age of 5 years (2 mths -21years), were included. They received a transplant (56 matched, 54 mismatched; 33 cord blood, 77 bone marrow; 33 family, 77 unrelated) for malignant (56) and non-malignant (54) disease, after a TBI (33) or chemotherapy based (77) conditioning regimen. In 50% of patients a RV infection occurred, at a median of day +16 (range -7 to 100). RV was proven by qPCR on nasopharyngeal aspirate: Rhinovirus was found most frequent (28), followed by Parainfluenzavirus1-3, Coronavirus, Influenza A virus and Adenovirus. Clinical symptoms were mild, and all patients recovered spontaneously, despite the fact that the RV remained present for months in all patients. After a period without symptoms of at least 2 weeks, new respiratory symptoms occurred in about 50% of the RV positive patients. Based on additional examinations including negative cultures (other than RV), radiology and pulmonary function tests, 30 patients (27.2%) were diagnosed with allo-LS: 18 IPS (16.4%) and 12 BO (10.9%), after a median time of 8 weeks (2-26). Multivariable analysis showed that RV infection is an important predictor for allo-LS (p \0.0001). There was no difference between Rhinovirus versus all others. Acute Graftversus-Host Disease (aGVHD), occurring at a median of 4 weeks (2-15), had a protective effect on the development of allo-LS (p 5 0.004), most likely due to higher and prolonged immunesuppression in these patients. Overall survival was 73%; in the allo-LS group this was only 53%. In multivariable analysis allo-LS was the only predictor for mortality (p5 0.04).
GVH/GVL
In conclusion, early presence of RV is a predictor for the development of allo-LS. We hypothesise that infection with a common cold virus makes the lung a target for alloimmunity, leading to life threatening lung disease. Paradoxically, prolonged immune suppression, despite the local viral infection, protected against the development of allo-LS.
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RAPID RECONSTITUTION OF THE REGULATORY T CELL COMPARTMENT AFTER HIGH DOSE CYCLOPHOSPHAMIDE IMMUNOSUPPRESSION PRE-VENTS THE DEVELOPMENT OF GVHD AFTER ALLOGENEIC BMT Hess, A.D., Fuchs, E.J., Luznik, L., Thoburn, C.J., Kos, F., Jones, R.J. The Johns Hopkins University, Baltimore, MD Graft-versus-host disease (GVHD) is a life-threatening complication of allogeneic bone marrow transplantation (BMT). Although the development of immunosuppressive regimens has reduced the incidence and severity of this post transplant complication, GVHD continues to be a significant clinical problem. There is also significant toxicity associated with the multi-agent immunosuppressive regimens. Recent studies revealed that high dose cyclophosphamide (Cy, 50 mg/kg) was effective at reducing the incidence of grades II-IV GVHD when administered as a single agent on days 3 and 4 following HLA matched related and unrelated BMT. The incidence of chronic GVHD was also reduced to 10%. The present studies evaluated the reconstitution of the CD4 + CD25 + Foxp3+ regulatory T cell compartment in patients treated with single agent high dose Cy. Peripheral blood lymphocytes (50 patients) were harvested on days 30, 45 and 60 post transplant and evaluated for Foxp3, IL-2 and IFN-g mRNA transcript levels by real time PCR and by enumeration of CD4 + CD25 + Foxp3 + T cells by flow cytometry. The results reveal that there was an inverse correlation of Foxp3 mRNA transcripts with the incidence of grades II-IV GVHD. Levels of Foxp3 mRNA transcripts in patients who did not develop GVHD were .100 fold greater than the levels detected in patients who developed GVHD. Interestingly, mRNA transcript levels of IL-2 and IFN-g were significantly increased (.100-1000 fold) in patients developing acute GVHD. Additional studies revealed that CD4 + CD25 + Foxp3 + T cells enumerated flow cytometrically in a subset of patients (16) were also detected at significant levels (30-50 cells/ ul) as early as day 30 in patients who did not develop GVHD. Comparatively, the number of CD4 + CD25 + Foxp3 + T cells in patients who developed acute GVHD was \10 cells/ul and remained persistently low even at day 60. The peripheral blood mononuclear cells were also assessed for T cell recombinant excision circles (TRECs) as a marker for recent thymic emigrants. Surprisingly, TRECs were not detected at day 30. Taken together, these results suggest that there is a rapid recovery of CD4 + CD25 + Foxp3+ regulatory T cells in the majority of patients treated with high dose Cy which may prevent the development of GVHD. The absence of TRECs in these patients may suggest that the expansion of the regulatory compartment may be antigen driven from a mature T cell population or expanded by homeostatic mechanisms. Introduction: Despite the inadequacy of current GvHD prophylaxis for MHC-mismatched HSCT, the introduction of novel therapeutics has been slow, likely due to the lack of a suitable translational model to rigorously test emerging therapies. Here we describe a novel Rhesus macaque model, which has allowed us to evaluate mechanisms controlling GvHD and its protection in a primate translational system. Methods: Using microsatellite-based MHC haplotyping, we developed the first MHC-defined primate HSCT system. HSCT recipients, prepared with 8 Gy TBI, received either no immunosuppression or a costimulation blockade-based regimen which included CD28 blockade (abatacept), CD40 blockade (with the anti-CD40 antibody 3A8) and sirolimus after MHC haploidentical sibling HSCT. Recipients received a TNC dose of 9.3 +/-2.7Â10 8 /kg and a CD3+ cell dose of 1.1 +/-0.88 Â 10 8 /kg. Results: Three control recipients (no immunosuppression) demonstrated rapid and complete donor engraftment, with T cell activation and proliferation occurring by Day 7, coincident with the onset of severe clinical GvHD. Flow cytometric analysis showed loss of S168 Oral Presentations
